Oxis is a beta 2-agonist that has a fast-acting, long-lasting bronchodilatory effect.
It include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
Oxis International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress.
Oxidative stress is caused by the unchecked activities of reactive oxygen species (ROS) and reactive nitrogen species (RNS).
Both ROS and RNS are highly reactive, unstable molecules that, in healthy cells, are created and neutralized as part of normal cell life.
Oxidative stress is also caused by inflammation, exposure to cigarette smoke, pollution, UV light, radiation, certain drugs and other conditions. Oxidative stress also increases as we age.
OXIS is developing and plans to sell Nutraceutical and Cosmecuetical products featuring natural ingredients believed to have beneficial effects on human health.
OXIS presently holds the rights to 4 therapeutic classes of compounds in the treatment of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as the super-potent antioxidant, Ergothioneine, that is planned to be introduced as an over-the-counter nutraceutical supplement.
By mimicking glutathione peroxidase (GPx), ALT-2074 may protect against excessive oxidation of lipids and thereby limit inflammation.
This compound may be useful in patients with diabetes, whose cardiovascular disease may be caused by high levels of circulating oxidized lipids and associated inflammation.
For more information visit : http://www.oxis.com, and for discussion and interactive you also can join their twitter and facebook at : Oxis on Twitter, Oxis on facebook
Entries (RSS)